Relief Therapeutics Holding Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Relief Therapeutics Holding şirketinin toplam hissedar öz sermayesi CHF49.3M ve toplam borcu CHF12.0K olup, bu da borç-öz sermaye oranını 0.02% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CHF70.9M ve CHF21.7M dir.

Anahtar bilgiler

0.02%

Borç/özkaynak oranı

CHF 12.00k

Borç

Faiz karşılama oranı	n/a
Nakit	CHF 10.73m
Eşitlik	CHF 49.27m
Toplam yükümlülükler	CHF 21.65m
Toplam varlıklar	CHF 70.92m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0QKQ 'nin kısa vadeli varlıkları ( CHF14.7M ) kısa vadeli yükümlülüklerini ( CHF4.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0QKQ 'un kısa vadeli varlıkları ( CHF14.7M ) uzun vadeli yükümlülüklerini ( CHF16.9M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0QKQ şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 0QKQ 'nin borç/öz sermaye oranı son 5 yılda 6.6% seviyesinden 0.02% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0QKQ şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 0QKQ serbest nakit akışı her yıl % 21.2 1 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 01:19
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Relief Therapeutics Holding SA 2 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Alexandre Müller	Research Dynamics
Bob Pooler	ValuationLAB AG

Relief Therapeutics Holding Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Relief Therapeutics Holding SA Announces Final Readout of PKU GOLIKE Clinical Trial

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million.

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Holding SA Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-Of-Concept Study; Topline Results Expected in October 2024

New minor risk - Shareholder dilution

New major risk - Share price stability

Relief Therapeutics Holding SA Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

Relief Therapeutics Holding SA to Report First Half, 2024 Results on Aug 30, 2024

Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors

Relief Therapeutics Holding SA, Annual General Meeting, Jun 27, 2024

Relief Therapeutics Announces Executive Changes

Full year 2023 earnings released: CHF8.35 loss per share (vs CHF4.81 loss in FY 2022)

New minor risk - Financial data availability

Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor

Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor

New minor risk - Share price stability

Less than half of directors are independent

Relief Therapeutics Holding Sa Announces CEO Changes

First half 2023 earnings released: CHF5.10 loss per share (vs CHF2.55 loss in 1H 2022)

New major risk - Financial position

Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding

New major risk - Share price stability

Relief Therapeutics Holding AG, Annual General Meeting, Jun 20, 2023

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-Of-Concept Clinical Trial of Rlf-Td011 for the Treatment of Epidermolysis Bullosa

RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ for Patients with Urea Cycle Disorders

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer

No independent directors

Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer

Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE

Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa At Ann & Robert H. Lurie Children's Hospital of Chicago

Relief Therapeutics Holding AG has filed an IPO.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation

Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access, Effective August 22, 2022

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for Review Acer’s Resubmitted New Drug Application

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Relief Therapeutics Expands U.S. Commercial Team

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Relief Therapeutics Holding AG, Annual General Meeting, May 31, 2022

No independent directors

Relief Therapeutics Holding AG Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing

Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Relief Therapeutics Holding SA Files Trademark Application for RLF-100 with the U.S. Patent and Trademark Office

Relief Therapeutics Holding AG Approves Election of Michelle Lock as New Member of the Board of Directors

NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics

Relief Therapeutics Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-Induced Pneumonitis

Relief Therapeutics Holding SA Announces New Safety Update on Aviptadil

Chief Commercial Officer Christiaan L. J. Stijnen has left the company

Relief Therapeutics Holding AG (SWX:RLF) completed the acquisition of APR Applied Pharma Research s.a.

Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA

Relief Provides Update on Progress and Plans with Acer-001 for the Treatment of Urea Cycle Disorders

Relief Therapeutics Holding AG (SWX:RLF) signed binding term sheet to acquire APR Applied Pharma Research s.a. for CHF.

Relief Therapeutics Successfully Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure Among Critically Iii Patients with Covid-19

NeuroRx and Relief Therapeutics Holding AG Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19

Director has left the company

RELIEF THERAPEUTICS Holding AG Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors

Relief Therapeutics Holding AG Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients

Relief Therapeutics Holding Ag and Acer Therapeutics Inc. Announces the Companies Have Signed an Option Agreement

Relief Therapeutics Holding AG (SWX:RLF) signed a binding term sheet to acquire AdVita Lifescience GmbH for €45 million.